Royalty Pharma reported a robust third quarter, achieving 11% growth in both portfolio and royalty receipts, alongside strong capital deployment, further solidifying its position in the life sciences sector.

• Achieved 11% growth in both portfolio and royalty receipts, reflecting the strength of a diversified portfolio.
• Deployed $1 billion in capital this quarter, bringing total deployments to $1.7 billion for the year, while repurchasing 4 million shares.
• Expanded development-stage pipeline to 17 therapies, with multiple pivotal readouts expected soon.
• Raised full-year 2025 portfolio receipts guidance again, now projecting growth of 14% to 16%, totaling between $3.2 billion and $3.25 billion.
• Committed over $1.6 billion in recent transactions, enhancing growth prospects in key therapeutic areas.